EUVIMEDEUVIMED entdecken
Klinische Studie (Phase IV)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

The efficacy and safety of Serenoa repens extract for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial

Kai Zhang, Run-Qi Guo, Shan-Wen Chen, Bin Chen, Xin-Bo Xue, Shan Chen, Jian Huang, Ming Liu, Ye Tian, Li Zuo, Ming Chen, Li-Qun Zhou

World Journal of Urology · 2021-09 · 39 (9) · 3489-3495

DOI: 10.1007/s00345-020-03577-2 ↗

Kurz gefasst

Klinische Studie (Phase IV) in der Zeitschrift World Journal of Urology, online erschienen am 16.01.2021. Verfasst von Kai Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Peking University First Hospital, The Institute of Urology, Peking University, National Urological Cancer Center, Beijing, 100…. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Honghui Pharmaceutical Co.,Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To perform a placebo-controlled trial to evaluate the efficacy and safety of Serenoa repens extract (SRE) for the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).

Methods

We conducted a double-blind, randomized, placebo-controlled, multicenter, clinical phase 4 study of 221 patients with CP/CPPS across 11 centers. Participants were randomly assigned in a 2:1 ratio to receive SRE or placebo for 12 weeks. The primary efficacy endpoint was the change in total score on the National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI). Secondary efficacy endpoints included improvements within each domain of NIH-CPSI, clinical response rate, and International Index of Erectile Function 5 items (IIEF-5).

Results

In total, 226 patients were enrolled and randomized between January 2017 and June 2018. Of these 221 patients were included in the intent-to-treat analysis: 148 in the SRE group and 73 patients in the placebo group. Compared to the placebo, SRE led to statistically significant improvements in the NIH-CPSI total score and sub-scores. The significant improvements of NIH-CPSI scores were established after 2 weeks from the first dose, and continued to the end of the treatment. Furthermore, a significantly higher rate of patients achieved a clinical response in the SRE group compared with that in the placebo group (73.0% vs 32.9%, P < 0.0001). Only minor adverse events were observed across the entire study population.

Conclusions

SRE was effective, safe, and clinically superior to placebo for the treatment of CP/CPPS. ChiCTR-IPR-16010196, December 21, 2016 retrospectively registered

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultDouble-Blind MethodHumansMalePlant ExtractsProstatitisSerenoaTreatment Outcome

Stichwörter der Autor:innen

Chronic pelvic pain syndromeChronic prostatitisEfficacySafetySerenoa repens

Substanzen

Plant ExtractsProstasan

Autor:innen und Institutionen

  • Department of Urology, Peking University First Hospital, The Institute of Urology, Peking University, National Urological Cancer Center, Beijing, 100034, China.
  • Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China.
  • Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Beijing, China.
  • Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Department of Urology, Huashan Hospital of Fudan University, Shanghai, China.
  • Department of Urology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Förderung

  • Jiangsu Honghui Pharmaceutical Co.,Ltd

Zitieren

APA

Zhang, K., Guo, R. Q., Chen, S. W., Chen, B., Xue, X. B., Chen, S., Huang, J., Liu, M., Tian, Y., Zuo, L., Chen, M., & Zhou, L. Q. (2021). The efficacy and safety of Serenoa repens extract for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial. World Journal of Urology, 39(9), 3489-3495. https://doi.org/10.1007/s00345-020-03577-2

Vancouver

Zhang K, Guo RQ, Chen SW, Chen B, Xue XB, Chen S, et al. The efficacy and safety of Serenoa repens extract for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial. World Journal of Urology. 2021;39(9):3489-3495. doi:10.1007/s00345-020-03577-2

BibTeX
@article{Zhang2021,
  author = {Zhang, Kai and Guo, Run-Qi and Chen, Shan-Wen and Chen, Bin and Xue, Xin-Bo and Chen, Shan and Huang, Jian and Liu, Ming and Tian, Ye and Zuo, Li and Chen, Ming and Zhou, Li-Qun},
  title = {The efficacy and safety of Serenoa repens extract for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome: a multicenter, randomized, double-blind, placebo-controlled trial},
  journal = {World Journal of Urology},
  year = {2021},
  volume = {39},
  number = {9},
  pages = {3489--3495},
  doi = {10.1007/s00345-020-03577-2}
}
Kostenlos starten →